{"title": "What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021", "author": "Jin-Hong Yoo", "url": null, "hostname": null, "description": null, "sitename": "Journal of Korean Medical Science", "date": "2021-02-02", "cleaned_text": "1. Yoo JH. Will the third wave of coronavirus disease 2019 really come in Korea? J Korean Med Sci. 2020; 35(10):e110. PMID: [32174068](http://www.ncbi.nlm.nih.gov/pubmed/32174068) . 2. Yoo JH. Social distancing and lessons from Sweden's lenient strategy against corona virus disease 2019. J Korean Med Sci. 2020; 35(27):e250. PMID: Rafaniello C, Zoccoli A, et al. Current pharmacological AH. COVID-19: a review of Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020; 383(19):1813-1826. PMID: [32445440](http://www.ncbi.nlm.nih.gov/pubmed/32445440) Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2020; 1-18. PMID: [31792373](http://www.ncbi.nlm.nih.gov/pubmed/31792373) . 9. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798):265-269. PMID: [32015508](http://www.ncbi.nlm.nih.gov/pubmed/32015508) . 11. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. 2020; 382(21):1969-1973. PMID: [32227757](http://www.ncbi.nlm.nih.gov/pubmed/32227757) . 12. Slaoui M, Hepburn M. Developing safe and effective Covid vaccines - operation warp speed's strategy and approach. N Engl J Med. 2020; Roscilli G, al. SARS-CoV-2 Lamirande EW, Murphy BR, Subbarao K, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Kolesnikova L, Uematsu Y, Gismondo MR, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med. 2004; 10(8):871-875. PMID: [15247913](http://www.ncbi.nlm.nih.gov/pubmed/15247913) . 17. Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor Immunol. 2020; 17(6):613-620. PMID: [32203189](http://www.ncbi.nlm.nih.gov/pubmed/32203189) . 18. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. M, Tyrrell DA. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990; 105(2):435-446. PMID: [2170159](http://www.ncbi.nlm.nih.gov/pubmed/2170159) . 20. W, Zhang PH, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus J Med. 2007; 357(11):1162-1163. [17855683](http://www.ncbi.nlm.nih.gov/pubmed/17855683) . 21. Wu LP, Wang NC, Chang YH, Tian XY, Na DY, Zhang LY, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007; 13(10):1562-1564. PMID: [18258008](http://www.ncbi.nlm.nih.gov/pubmed/18258008) . 22. Oh JO, Ahn JY, Choi H, Kim JH, Seong H, et al. Absence of neutralizing activity in serum 1 year after successful treatment with antivirals and recovery from MERS in South Korea. Clin Res. 2019; 8(1):86-88. PMID: [30775355](http://www.ncbi.nlm.nih.gov/pubmed/30775355) . 23. Sariol A, Perlman S. Lessons for COVID-19 immunity from other coronavirus infections. Immunity. 2020; 53(2):248-263. PMID: [32717182](http://www.ncbi.nlm.nih.gov/pubmed/32717182) . 24. Bachmann Mohsen MO, Zha L, Vogel M, Speiser DE. SARS-CoV-2 structural features may T cell priming as biomarker to study immune response preventive 4:421. PMID: Mateus J, Dan JM, Moderbacher CR, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. 2020; 181(7):1489-1501.e15. PMID: [32473127](http://www.ncbi.nlm.nih.gov/pubmed/32473127) . 27. Chen K, Kolls JK. T cell-mediated host immune defenses in 31(1):605-633. PMID: [23516986](http://www.ncbi.nlm.nih.gov/pubmed/23516986) . 28. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Benslimane FM, Al Thani AA, Zaraket H, et al. Platforms exploited for SARS-CoV-2 vaccine development. Vaccines (Basel). 2020; 9(1):E11. PMID: [33375677](http://www.ncbi.nlm.nih.gov/pubmed/33375677) . 31. Zhang C, Zhou D. Adenoviral vector-based strategies against infectious disease immunity against Ad vectors: humoral, cellular, and Smith BK, Harvey IB, et al. A Single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts SARS-CoV-2. Cell. 2020; 183(1):169-184.e13. PMID: [32931734](http://www.ncbi.nlm.nih.gov/pubmed/32931734) . 34. Ewer K, Sebastian S, Spencer AJ, Gilbert S, Hill AV, Lambe T. Chimpanzee adenoviral vectors as vaccines Zhou D. Development of novel vaccine vectors: Ammendola V, Capone S, Cirillo A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012; 4(115):115ra2. 38. van Doremalen N, Lambe T, Spencer A, S, Purushotham JN, Port JR, et al. ChAdOx1 LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397(10269):99-111. rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from . C, Chandrashekar A, Yu J, et al. Single-shot Ad26 vaccine Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1-2a Trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021; WJ, Li JX, et Safety, tolerability, and immunogenicity of FW, Weissman D. mRNA vaccines - a new era in Rev Drug Discov. 2018; 17(4):261-279. PMID: [29326426](http://www.ncbi.nlm.nih.gov/pubmed/29326426) Wibowo N, Zhao CX, Mitter N, Yu C, PMID: FA, Ludwig J, Kato H, Akira S, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased Silverman RH, Weissman D, Karik\u00f3 K. Nucleoside modifications in RNA limit activation of 2-5-oligoadenylate synthetase and increase resistance to cleavage Krayukhina E, Taoka M, Yamauchi Y, et al. Structural analysis reveals that Toll-like receptor 7 is a dual receptor for guanosine and RNA. Buckstein M, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; PMID: Yamauchi Y, Isobe T, et al. Toll-like receptor 8 senses degradation products of the osmoregulated promoter-derived proP mRNA is posttranscriptionally regulated . 56. Knights AJ, Nuber CW, de la Rosa O, J\u00e4ger E, Tiercy JM, et al. Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells NW, Giles M, Koirala A, Macartney K, et al. Progress and pitfalls in the quest for effective SARS-CoV-2 (COVID-19) vaccines. Front Immunol. 2020; Wang F, Stefano GB. An evidence based perspective on mRNA-SARS-CoV-2 development. Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl S, Kaczmarek Hurtado JE, Yang JH, et al. Efficacy and immunogenicity of unmodified and Boyer JD, Reuschel EL, Patel A, Christensen-Quick A, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, phase 1 clinical trial. EClinicalMedicine. 2020; 31:100689. PMID: [33392485](http://www.ncbi.nlm.nih.gov/pubmed/33392485) . 65. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine aged 18-59 years: a randomised, double-blind, placebo-controlled, phase Dis. 2020; 21(2):181-192. PMID: [33217362](http://www.ncbi.nlm.nih.gov/pubmed/33217362) . 66. Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020; 182(3):713-721.e9. PMID: [32778225](http://www.ncbi.nlm.nih.gov/pubmed/32778225) . 67. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, . MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 Rev Immunol. 2020; 20(10):615-632. PMID: vaccines: \"warp speed\" needs mind 94(17):e01083-20. PMID: [32591466](http://www.ncbi.nlm.nih.gov/pubmed/32591466) . 70. Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA. Forthcoming. 2021; DOI: [10.1001/jama.2021.0600](https://doi.org/10.1001/jama.2021.0600) . 76. Emergency use authorization (EUA) of The Pfizer-Biontech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) in individuals 16 years of age and older. Updated 2020. Accessed January 31, 2021. [https://www.fda.gov/media/144414/download](https://www.fda.gov/media/144414/download) . 77. Emergency use authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) In Individuals 18 years of age and older. Updated 2020. Accessed January 31, 2021. [https://www.fda.gov/media/144638/download](https://www.fda.gov/media/144638/download) . 78. Cabanillas B, Akdis C, Novak N. Allergic reactions to the first COVID-19 vaccine: a potential role of Polyethylene glycol? Allergy. Forthcoming. [10.1111/all.14711](https://doi.org/10.1111/all.14711) al. Pre-existing anti-polyethylene glycol linked to first-exposure allergic reactions to 82. Mallapaty S, Ledford H. COVID-vaccine results are on the way - and scientists' concerns are growing. Nature. 2020; 586(7827):16-17. PMID: [32978611](http://www.ncbi.nlm.nih.gov/pubmed/32978611) . 85. Centers for Disease Control and Prevention (CDC). Syncope after vaccination--United States, January I. Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination. BMJ. 2021; 372(149):n149. PMID: [33451975](http://www.ncbi.nlm.nih.gov/pubmed/33451975) . 87. Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J . 88. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev PMID: [32908214](http://www.ncbi.nlm.nih.gov/pubmed/32908214) . 90. Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev vaccine design: the Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg et al. Humoral immune response to SARS-CoV-2 in N Anderson EJ, Roberts PC, Makhene M, et al. Durability of responses after SARS-CoV-2 mRNA-1273 N Arm-Vernez I, Baggio S, Didierlaurent A, et al. Antibody persistence in the first six months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study. Clin KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. Forthcoming. 2021; DOI: [10.1126/science.abf4063](https://doi.org/10.1126/science.abf4063) . 99. Wise J. Covid-19: Yoon H, Theiler J, Abfalterer W, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity 2020; 182(4):812-827.e19. [32697968](http://www.ncbi.nlm.nih.gov/pubmed/32697968) 101. Callaway E. Could new COVID variants undermine vaccines? Labs scramble to find out. Nature. 2021; 589(7841):177-178. PMID: [33432212](http://www.ncbi.nlm.nih.gov/pubmed/33432212) . 103. Weisblum F, DaSilva J, Poston D, Lorenzi JC, et al. Escape Bai H, Li Y, Reeves DB, Joyce MG, et al. A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants. Proc Natl Collier DA, Meng B, Ferreira IA, Datir R, Temperton N, Elmer A, et al. Impact of SARS-CoV-2 B.1.1.7 Spike variant on neutralisation potency of sera from individuals vaccinated with Pfizer vaccine BNT162b2. Updated 2021. Accessed January 31, 2021. [https://www.medrxiv.org/content/10.1101/2021.01.19.21249840v1](https://www.medrxiv.org/content/10.1101/2021.01.19.21249840v1) . 107. Kistler KE, Bedford T. Evidence for adaptive evolution in the receptor-binding domain of [33479534](http://www.ncbi.nlm.nih.gov/pubmed/33479534) . 111. De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev Infect of remdesivir to SARS-CoV-2 RNA-dependent RNA polymerase may pave the way towards the design of potential drugs for COVID-19 treatment. Curr Pharm Biotechnol. Forthcoming. 2020; DOI: [10.2174/1389201021666201027154833](https://doi.org/10.2174/1389201021666201027154833) . 114. Pan X, Dong L, Yang L, Chen D, Peng C. Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China. Virus Res. 2020; 286:198057. PMID: [32531236](http://www.ncbi.nlm.nih.gov/pubmed/32531236) . 115. Yuan S, Chan CC, Chik KK, Tsang JO, Liang R, Cao J, et al. Broad-spectrum host-based antivirals targeting the interferon and lipogenesis pathways as potential treatment options for the pandemic coronavirus disease 2019 (COVID-19). Viruses. 2020; 12(6):628. 116. Boras RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, et of a novel inhibitor of coronavirus 3CL protease as a clinical candidate for the potential treatment of COVID-19. Updated 2021. Accessed January 31, 2021. [https://www.biorxiv.org/content/10.1101/2020.09.12.293498v2](https://www.biorxiv.org/content/10.1101/2020.09.12.293498v2) . 117. Zhang WF, P, Th\u00e9riault Lin SX. Novel coronavirus polymerase and nucleotidyl-transferase structures: potential to N, Gulyaeva A, et al. Coronavirus replication-transcription complex: vital and selective NMPylation of by the "}